Top

Published in:

01-05-2017 | Original Article

Role of benzydamine hydrochloride in the prevention of oral mucositis in head and neck cancer patients treated with radiotherapy (>50 Gy) with or without chemotherapy

Authors: Madhup Rastogi, Rohini Khurana, Swaroop Revannasiddaiah, Isha Jaiswal, Sambit S Nanda, Pooja Gupta, Kundan S Chufal, M L Bhatt

Published in: Supportive Care in Cancer | Issue 5/2017

Abstract

Purpose

Benzydamine is recommended for prophylaxis of oral mucositis (OM) in head and neck cancer (HNC) patients for radiation doses (<50 Gy). This study evaluates role of benzydamine for higher radiation doses (>50 Gy) with or without chemotherapy.

Methods

One hundred twenty patients of HNC with planned radiation doses of ≥60 Gy were randomized to group A (control radiotherapy alone), group B (study radiotherapy alone), group C (control chemoradiotherapy), or to group D (study chemoradiotherapy). Groups A and C were advised saline mouth rinses, and in groups B and D, additional benzydamine rinses (0.15%) were advised. Mucositis grading was done with both WHO (WHO-M) and CTCAE (CTC-M) version 4.0 (common terminology criteria for adverse events) weekly.

Results

Patient characteristics are presented in the table. Patients in group B had lesser grade 3 WHO-M and CTC-M as compared to group A, 62.1 vs. 36.4% (p = 0.038) and 51.7 vs. 27.3% (p = 0.043), respectively. The rates of Ryle’s tube feeding (RTF), intravenous fluid supplementation (IVF), and hospitalization were also lesser in group B as compared to A, 34.5 vs. 21.2% (p = 0.18), 27.6 vs. 9.1% (p = 0.06), and 6.9 vs. 0% (p = 0.21), respectively. WHO-M and CTC-M in groups C and D were not statistically different, 64.3 vs. 43.3% (p = 0.091) and 53.6% vs. 43.3% (p = 0.30), respectively. The rates of RTF, IVF, and hospitalization were all lesser but p > 0.05.

Conclusion

Benzydamine significantly reduces OM even at doses >50 Gy in HNC patients. Its role in patients receiving concurrent chemotherapy further needs to be evaluated.

Joshi P, Dutta S, Chaturvedi P, Nair S. (2014) Head and neck cancers in developing countries. Rambam Maimonides Med J [Internet]. Apr 28 [cited 2016 Sep 27];5(2). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011474/

Nandakumar A (2016) Survival in head and neck cancers—results of a multi-institution study. Asian Pac J Cancer Prev 17(4):1745–1754CrossRefPubMed

Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK et al (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. RadiotherOncol J EurSocTherRadiolOncol 66(3):253–262

Bese NS, Hendry J, Jeremic B (2007) Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J RadiatOncolBiol Phys 68(3):654–661

Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9 Suppl):2026–2046CrossRefPubMed

McGuire DB, Correa MEP, Johnson J, Wienandts P (2006) The role of basic oral care and good clinical practice principles in the management of oral mucositis. Support Care Cancer Off J MultinatlAssoc Support Care Cancer 14(6):541–547CrossRef

Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM et al (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120(10):1453–1461CrossRefPubMedPubMedCentral

Machiels J-P, Lambrecht M, Hanin F-X, Duprez T, Gregoire V, Schmitz S, et al. (2014) Advances in the management of squamous cell carcinoma of the head and neck. F1000Prime Rep [Internet]. Jun 2 [cited 2016 Sep 27];6. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047945/

Yeh S-A (2010) Radiotherapy for head and neck cancer. SeminPlast Surg 24(2):127–136

10.

Lalla RV, Sonis ST, Peterson DE (2008) Management of oral mucositis in patients with cancer. Dent Clin N Am 52(1):61–77CrossRefPubMedPubMedCentral

11.

Elting LS, Cooksley CD, Chambers MS, Garden AS (2007) Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J RadiatOncolBiol Phys 68(4):1110–1120

12.

Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE et al (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109(5):820–831CrossRefPubMed

13.

Epstein JB, Stevenson-Moore P, Jackson S, Mohamed JH, Spinelli JJ (1989) Prevention of oral mucositis in radiation therapy: a controlled study with benzydamine hydrochloride rinse. Int J RadiatOncolBiol Phys 16(6):1571–1575

14.

Epstein JB, Silverman S, Paggiarino DA, Crockett S, Schubert MM, Senzer NN et al (2001) Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 92(4):875–885CrossRefPubMed

15.

Kazemian A, Kamian S, Aghili M, Hashemi FA, Haddad P (2009) Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial. Eur J Cancer Care (Engl) 18(2):174–178CrossRef

16.

Sheibani KM, Mafi AR, Moghaddam S, Taslimi F, Amiran A, Ameri A (2015) Efficacy of benzydamine oral rinse in prevention and management of radiation-induced oral mucositis: a double-blind placebo-controlled randomized clinical trial. Asia Pac J ClinOncol 11(1):22–27CrossRef

17.

Kamian S (2007) Benzydamine for prophylaxis of radiation induced oral mucositis in head and neck cancers: double-blind clinical trial. ASCO Meet Abstr 25(18_suppl):9042

18.

Kim JH, Chu FC, Lakshmi V, Houde R (1986) Benzydamine HCl, a new agent for the treatment of radiation mucositis of the oropharynx. Am J ClinOncol 9(2):132–134CrossRef

Title: Role of benzydamine hydrochloride in the prevention of oral mucositis in head and neck cancer patients treated with radiotherapy (>50 Gy) with or without chemotherapy
Authors: Madhup Rastogi
Rohini Khurana
Swaroop Revannasiddaiah
Isha Jaiswal
Sambit S Nanda
Pooja Gupta
Kundan S Chufal
M L Bhatt
Publication date: 01-05-2017
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 5/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-016-3548-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2017

Triathlon training for women breast cancer survivors: feasibility and initial efficacy

Erratum to: Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types

Patterns of statin initiation and continuation in patients with breast or colorectal cancer, towards end-of-life

A prospective exploration of symptom burden clusters in women with breast cancer during chemotherapy treatment

Quality of life of older African American breast cancer survivors: a population-based study

Predictive performance of the quick Sequential Organ Failure Assessment score as a screening tool for sepsis, mortality, and intensive care unit admission in patients with febrile neutropenia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer